The National Pharmaceutical Pricing Authority (NPPA) has increased the ceiling prices of eight essential drugs by 50%, citing rising production costs and concerns over drug availability. The move aims to ensure the continued production and accessibility of these crucial medications for conditions like asthma, glaucoma, and tuberculosis.
The Indian government has adjusted prices for several essential drugs, including those for diabetes, hypertension, heart disease, bacterial infections, and allergies. While some medications saw an increase, others, such as metformin and ciprofloxacin, experienced price reductions. The NPPA’s decision was based on recent changes in wholesale inflation and aims to ensure the availability of essential medicines at affordable prices.
In a bid to make healthcare more accessible, the Indian government has announced significant price reductions for 41 commonly used medicines and six formulations. These revised prices target various conditions, including diabetes, cardiovascular diseases, liver issues, infections, allergies, multivitamins, and antibiotics. This move is expected to benefit millions of patients who rely on these essential medications. The decision was made by the National Pharmaceutical Pricing Authority (NPPA) during its 143rd meeting.
